Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,657,250 | 966,428 | 812,688 | 866,394 | 819,975 |
| Marketable Securities | 1,251,234 | 1,728,076 | 1,626,694 | 1,326,012 | 1,615,589 |
| Receivables | 777,567 | 405,308 | 327,787 | 237,963 | 198,571 |
| Inventories | 82,719 | 78,509 | 89,146 | 128,962 | 86,363 |
| TOTAL | $4,050,662 | $3,295,285 | $2,982,697 | $2,692,247 | $2,808,576 |
| Non-Current Assets | |||||
| PPE Net | 513,147 | 502,784 | 526,057 | 523,494 | 501,958 |
| Investments And Advances | 22,170 | 68,593 | 49,391 | 49,390 | 40,891 |
| Other Non-Current Assets | 380,352 | 373,321 | 271,735 | 281,228 | 291,879 |
| TOTAL | $915,669 | $944,698 | $847,183 | $854,112 | $834,728 |
| Total Assets | $4,966,331 | $4,239,983 | $3,829,880 | $3,546,359 | $3,643,304 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 115,721 | 88,415 | 55,519 | 98,094 | 73,426 |
| Accrued Expenses | 1,080,197 | 793,692 | 713,013 | 545,460 | 395,174 |
| Other current liabilities | 220,068 | 206,798 | 54,991 | 40,289 | 37,079 |
| TOTAL | $1,466,349 | $1,186,272 | $967,786 | $767,915 | $695,710 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | N/A | 675,697 |
| Deferred Revenues | 4,845 | 55,481 | 102,753 | 42,105 | 149,483 |
| Other Non-Current Liabilities | 2,710,806 | 2,986,623 | 2,894,563 | 2,742,876 | 1,531,334 |
| TOTAL | $2,710,806 | $2,986,623 | $3,082,738 | $2,936,667 | $2,359,391 |
| Total Liabilities | $4,177,155 | $4,172,895 | $4,050,524 | $3,704,582 | $3,055,101 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 132,623 | 129,457 | 125,946 | 124,131 | 120,211 |
| Common Shares | 1,324 | 1,293 | 1,259 | 1,240 | 1,202 |
| Retained earnings | -6,702,524 | -7,287,748 | -7,009,591 | -6,569,349 | -5,438,193 |
| Other shareholders' equity | -20,097 | -34,518 | -23,375 | -44,654 | -33,259 |
| TOTAL | $789,176 | $67,088 | $-220,644 | $-158,223 | $588,203 |
| Total Liabilities And Equity | $4,966,331 | $4,239,983 | $3,829,880 | $3,546,359 | $3,643,304 |